UNSPSC 51294101: Dexnafenodone

This classification denotes an antidepressant agent with the molecular formula C20H23NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 601X8G3PCW, chemically known as 1(2h)-naphthalenone, 3,4-dihydro-2-(2-(dimethylamino)ethyl)-2-phenyl-, (s)- but generally known as dexnafenodone, which bears US NIH Compound Identifier 65834. European Medicines Agency schedules Dexnafenodone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07038MIG.

UNSPSC 51294101 Dexnafenodone is a Commodity code that shows little relevant recent activity. The three state and local opportunities tagged under this code—a Seminole County, Florida procurement for naloxone and drug deactivation systems, a Texas HHS Request for Information on direct-to-manufacturer prescriptions, and a Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP for generic multi-source pharmaceuticals and OTC products—do not align with the narrowly defined scope of dexnafenodone, a specific pharmaceutical compound. The solicitations cover naloxone (a different active pharmaceutical ingredient used for opioid overdose reversal), pharmacy benefit program administration and direct-to-manufacturer contracting strategies, and generic pharmaceutical sourcing across multiple drug categories, none of which match the code's pharmaceutical specificity. State and local procurement offices appear to use this code inconsistently or to tag broader pharmaceutical procurement activity that falls outside dexnafenodone's actual substance and clinical use.

The geographic spread across Florida, Texas, and Minnesota reflects general pharmaceutical procurement by counties, state health agencies, and regional cooperative purchasing vehicles, but the code's narrow definition and the mismatch between its name and the actual work being solicited suggest that this code does not represent a meaningful procurement category in current state and local practice. Vendors pursuing pharmaceutical supply contracts should monitor codes tagged to general generic or OTC product procurement, naloxone-specific sourcing, and pharmacy benefit program administration rather than rely on this commodity designation for actionable opportunity signals.